Verywell Health on MSN1y
What Is Bull’s-Eye Maculopathy?
Medically reviewed by Andrew Greenberg, MD Bull’s-eye maculopathy is an eye problem that affects the macula, the part of the ...
WebMD1mon
FDA OKs First Gene Therapy Implant for a Rare Eye Disease
March 7, 2025 – The FDA has approved a new gene therapy for macular telangiectasia type 2 (MacTel), a rare eye disease that causes vision loss. The approval marks the first and only ...
Medpage Today on MSN1mon
FDA Approves Ocular Implant for Vision-Threatening MacTel
The FDA approved revakinagene taroretcel (Encelto) as the first treatment for adults with idiopathic macular telangiectasia .
pharmaphorum1mon
Neurotech's cell therapy gets FDA nod for eye disorder MacTel
Neurotech Pharma's cell therapy Encelto has become the first FDA-approved treatment for idiopathic macular telangiectasia type 2 (MacTel), a rare eye disease leading to progressive and ...
Orange County Business Journal14d
FDA Greenlights Mazzo’s Neurotech Implant
The biotech company, focused on developing treatments for chronic eye conditions, received Food and Drug Administration (FDA) ...
FiercePharma28d
Neurotech nabs FDA approval to treat rare eye disorder with cell therapy implant Encelto
The FDA last week approved (PDF) Neurotech’s cell therapy implant revakinagene taroretcel to treat the vision-robbing neurodegenerative disease macular telangiectasia (MacTel) type 2.
The American Journal of Managed Care13d
Revakinagene Taroretcel Approval Addresses Unmet Need in MacTel
Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, discusses data supporting the FDA approval of revakinagene taroretcel-lwey (Encelto; Neurotech Pharmaceuticals), the first and only therapy ...